Seeking Novel Druggable Targets in Neuroinflammation and Neuroimmunity

Servier, a leading international pharmaceutical company, is seeking novel therapeutic proposals that target neuroinflammation and/or neuroimmunity in central nervous system and/or peripheral nervous system diseases. The team is particularly interested in approaches that have an already identified target, demonstrate the ability to counteract these pathological conditions, and offer a well-supported and differentiating pharmacological strategy for treatment. 

Approaches of Interest:

• Diseases of interest are ALS (sporadic form and neuroinflammation associated with genetic form), autoimmune myasthenia gravis, chronic inflammatory demyelinating polyneuropathies, autoimmune nodopathies, autoimmune epilepsy, and autoimmune encephalitis 
• Other neuroinflammatory/ neuroimmune diseases will be considered but as a lower priority and only if they have a clear identified target. In all cases, the eligible patient population should be over 500 individuals 
• Modalities of interest include small molecules, antibodies, and antisense oligonucleotides
• All targets and mechanisms of action related to neuroinflammation and/or neuroimmunity are in scope 
• Drug repurposing is of interest, provided there is clearly demonstrated involvement and proof of concept for one of the diseases of interest 

Out of Scope:

• Cell therapy, gene therapy, and medical devices 
• Broad or not-targeted anti-inflammatory approaches 

Developmental Stages of Interest:

• Opportunities up to late preclinical stage are of interest, provided there is clear proof of concept, at least in vitro
• Opportunities with in vivo proof of concept will be given priority 

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications or supporting materials/ experimental data. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.